Our Offering
Biologics
Mammalian
Microbial
ADCs / Bioconjugates
Drug Product
mRNA / LNP
Expression Technologies
Small Molecules
Drug Substance (API)
Particle Engineering
Drug Product
Cell & Gene
Process Development
cGMP manufacturing
Allogeneic
Autologous
Viral Vectors
Bioscience Products
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Our Company
About Us
Purpose and Strategy
Leadership
History
Locations
Partnering with Us
Events
News and Media
News Archive
Media Library
Logo Guidelines
Blog
Podcast
Media Inquiries
Investor Relations
Shareholder Information
Agenda and Events
Financial Reporting
Annual Report
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Performance
People
Planet
Community
Global Quality
Responsible Sourcing
Careers
Overview
Life at Lonza
What We Offer
Career Stories
Job Search
Join Our Talent Community
Recruitment Process
Students, Graduates and Apprentices
Contact
Our Offering
Corporate
Biologics
Mammalian
Microbial
ADCs / Bioconjugates
Drug Product
mRNA / LNP
Expression Technologies
Small Molecules
Drug Substance (API)
Particle Engineering
Drug Product
Cell & Gene
Process Development
cGMP manufacturing
Allogeneic
Autologous
Viral Vectors
Bioscience Products
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Our Company
Corporate
About Us
Purpose and Strategy
Leadership
History
Locations
Partnering with Us
Events
News and Media
News Archive
Media Library
Logo Guidelines
Blog
Podcast
Media Inquiries
Investor Relations
Shareholder Information
Agenda and Events
Financial Reporting
Annual Report
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Performance
People
Planet
Community
Global Quality
Responsible Sourcing
Careers
Corporate
Overview
Life at Lonza
What We Offer
Career Stories
Job Search
Join Our Talent Community
Recruitment Process
Students, Graduates and Apprentices
Contact
Corporate
Home
Knowledge Center
Making it happen: the road to commercial-scale
Making it happen: the road to commercial-scale
31 Aug 2018 | Content Type: Video
1h webinar focused on CT technology platforms including autologous, 3D bioreactors, iPSCs.
First Name
Last Name
Business Email
Company Name
Country
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas (the)
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia (Plurinational State of)
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory (the)
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands (the)
Central African Republic (the)
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands (the)
Colombia
Comoros (the)
Congo (the)
Congo (the Democratic Republic of the)
Cook Islands (the)
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curacao
Cyprus
Czechia
Denmark
Djibouti
Dominica
Dominican Republic (the)
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Falkland Islands (the) [Malvinas]
Faroe Islands (the)
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories (the)
Gabon
Gambia (the)
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (the)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran (Islamic Republic of)
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea (the Democratic People's Republic of)
Korea (the Republic of)
Kuwait
Kyrgyzstan
Lao People's Democratic Republic (the)
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands (the)
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia (Federated States of)
Moldova (the Republic of)
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands (the)
New Caledonia
New Zealand
Nicaragua
Niger (the)
Nigeria
Niue
Norfolk Island
North Macedonia
Northern Mariana Islands (the)
Norway
Oman
Pakistan
Palau
Palestine, State of
Panama
Papua New Guinea
Paraguay
Peru
Philippines (the)
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation (the)
Rwanda
Saint Barthelemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan (the)
Suriname
Svalbard and Jan Mayen
Sweden
Switzerland
Syrian Arab Republic (the)
Taiwan (Province of China)
Tajikistan
Tanzania, the United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands (the)
Tuvalu
Uganda
United Kingdom
Ukraine
United Arab Emirates (the)
United States Minor Outlying Islands (the)
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela (Bolivarian Republic of)
Viet Nam
Virgin Islands (British)
Virgin Islands (U.S.)
Global
Wallis and Futuna
Western Sahara*
Yemen
Zambia
Zimbabwe
State
Alaska
Alabama
Arkansas
American Samoa
Arizona
California
Colorado
Connecticut
District of Columbia
Delaware
Florida
Georgia
Guam
Hawaii
Iowa
Idaho
Illinois
Indiana
Kansas
Kentucky
Louisiana
Massachusetts
Maryland
Maine
Michigan
Minnesota
Missouri
Northern Mariana Islands
Mississippi
Montana
North Carolina
North Dakota
Nebraska
New Hampshire
New Jersey
New Mexico
Nevada
New York
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
U.S. Minor Outlying Islands (cf. separate entry UM)
Utah
Virginia
Virgin Islands of the U.S.
Vermont
Washington
Wisconsin
West Virginia
Wyoming
Join our community to receive tailored insights and resources. You can unsubscribe at any time.
By clicking "Access Content" you agree to our
Legal Disclaimer
and the
Lonza Privacy and Cookies Policy
.
Loading...
Latest content
Latest briefing from the Knowledge Center
Webinar (on-demand)
Scale up Considerations for Dry Powder Inhaler Manufacturing by Spray Drying
Spray drying is a versatile particle-engineering tool used to produce respirable dry powders of...
R&D Blog post
Developing Breakthrough Technology for Oral Solid Dosage Forms
Delivering treatment in the small intestine and not the stomach represents a unique drug delivery...
Whitepaper/Executive Summary
Reducing Wastewater Incineration and Carbon Emission
As the pharmaceutical industry works to develop more sustainable processes for large-scale drug...
Whitepaper/Executive Summary
Overcome Challenges And Secure Successful Technology Transfers Of Complex Biological Products In...
A critical area to consider in selecting a CDMO is their ability to successfully complete technology...
Video
The CDMO Value Proposition of Experience for Your Autologous Cell Therapy
bluebird bio and Lonza take the opening plenary stage at the CAR-TCR Summit to tell the story of...
Article
Addressing Challenges with Clinical In-Use Testing of Biotherapeutics
The goal of in-use testing of biotherapeutics is to ensure acceptable product quality during dose...
Article
How to Accelerate Your Biotherapeutics' Path to Clinic
Over the last few decades, many novel biotherapeutics have undergone clinical trial testing in the...
Peer-reviewed publication
Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon® Platform
Abstract: Autologous cell-based therapeutics have gained increasing attention in recent years...
Article
Strategies to Optimize Expression Challenges of Multi-chain and Bispecific Antibodies
Many of today's expression platforms for recombinant protein manufacturing have been optimised for...
Webinar (on-demand)
Transfer and Development of Mammalian Processes: Effective technology transfer for mammalian derived...
Translating innovations from research laboratories to clinical and commercial manufacturing is a...
Article
Tools for Developing Successful Biologics - XS Pichia® Expression System
Lonza subject matter experts talk about the XS® Pichia Expression System and how it could benefit...
Article
Successfully Transitioning mRNA Production to cGMP Requires Early Process Engagement for Developing...
Discover why early process optimization is key to developing an efficient, cost-effective cGMP...
Previous
Next